ACOT9

Across TCGA pan-cancer cohorts, ACOT9 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of ACOT9’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ACOT9 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ACOT9 is over-expressed in tumor, although a few such as KICH and LUSC show the opposite, repressed pattern.

HNSC, COAD, and LIHC are the cancer types where ACOT9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACOT9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	III,IV	+1.662	<.001	12	view →
COAD	Male	IV	+1.124	<.001	11	view →
LIHC	Male	II,III,IV	+1.174	<.001	9	view →
KICH	Female	All	−1.239	<.001	8	view →
LUSC	All	All	−0.354	<.001	7	view →
READ	Male	All	+1.180	.001	6	view →
BRCA	All	III,IV	−0.662	<.001	6	view →
CHOL	Male	All	+2.111	<.001	5	view →
STAD	All	II,III,IV	+0.644	.009	3	view →
ESCA	All	All	+1.081	.002	2	view →
PRAD	All	All	−0.214	.042	2	view →
THCA	Male	All	+0.252	.011	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

ACOT9–HNSC

Open the HNSC breakdown →